Your browser doesn't support javascript.
loading
Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer.
Martins, Filipe Correia; Couturier, Dominique-Laurent; de Santiago, Ines; Sauer, Carolin Margarethe; Vias, Maria; Angelova, Mihaela; Sanders, Deborah; Piskorz, Anna; Hall, James; Hosking, Karen; Amirthanayagam, Anumithra; Cosulich, Sabina; Carnevalli, Larissa; Davies, Barry; Watkins, Thomas B K; Funingana, Ionut G; Bolton, Helen; Haldar, Krishnayan; Latimer, John; Baldwin, Peter; Crawford, Robin; Eldridge, Matthew; Basu, Bristi; Jimenez-Linan, Mercedes; Mcpherson, Andrew W; McGranahan, Nicholas; Litchfield, Kevin; Shah, Sohrab P; McNeish, Iain; Caldas, Carlos; Evan, Gerard; Swanton, Charles; Brenton, James D.
Affiliation
  • Martins FC; Department of Obstetrics and Gynaecology, University of Cambridge, Cambridge, UK. f.correiamartins@nhs.net.
  • Couturier DL; Experimental Medicine Initiative, University of Cambridge, Cambridge, UK. f.correiamartins@nhs.net.
  • de Santiago I; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK. f.correiamartins@nhs.net.
  • Sauer CM; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. f.correiamartins@nhs.net.
  • Vias M; Department of Gynaecological Oncology, Cambridge University Hospitals, Cambridge, UK. f.correiamartins@nhs.net.
  • Angelova M; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
  • Sanders D; Medical Research Council Biostatistics Unit, University of Cambridge, Cambridge, UK.
  • Piskorz A; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
  • Hall J; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
  • Hosking K; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
  • Amirthanayagam A; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
  • Cosulich S; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
  • Carnevalli L; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
  • Davies B; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
  • Watkins TBK; Cambridge University Hospitals, Cambridge, UK.
  • Funingana IG; Department of Gynaecological Oncology, Cambridge University Hospitals, Cambridge, UK.
  • Bolton H; Early Oncology R&D, Astrazeneca, Cambridge, UK.
  • Haldar K; Early Oncology R&D, Astrazeneca, Cambridge, UK.
  • Latimer J; Early Oncology R&D, Astrazeneca, Cambridge, UK.
  • Baldwin P; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
  • Crawford R; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
  • Eldridge M; Department of Oncology, University of Cambridge, Cambridge, UK.
  • Basu B; Department of Gynaecological Oncology, Cambridge University Hospitals, Cambridge, UK.
  • Jimenez-Linan M; Department of Gynaecological Oncology, Cambridge University Hospitals, Cambridge, UK.
  • Mcpherson AW; Department of Gynaecological Oncology, Cambridge University Hospitals, Cambridge, UK.
  • McGranahan N; Department of Gynaecological Oncology, Cambridge University Hospitals, Cambridge, UK.
  • Litchfield K; Department of Gynaecological Oncology, Cambridge University Hospitals, Cambridge, UK.
  • Shah SP; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
  • McNeish I; Cambridge University Hospitals, Cambridge, UK.
  • Caldas C; Department of Oncology, University of Cambridge, Cambridge, UK.
  • Evan G; Department of Histopathology, Cambridge University Hospitals, Cambridge, UK.
  • Swanton C; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Centre, NYC, USA.
  • Brenton JD; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Nat Commun ; 13(1): 6360, 2022 10 26.
Article in En | MEDLINE | ID: mdl-36289203
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Cystadenocarcinoma, Serous Type of study: Diagnostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2022 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Cystadenocarcinoma, Serous Type of study: Diagnostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2022 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom